ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc. (ENTA) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D+). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B- (3.0) | D+ (1.6) | B- (3.0) | C+ (2.5) | C+ (2.6) | C+ (2.6) |
| 2026-11-04 | B- (3.0) | D+ (1.6) | B- (3.1) | C (2.5) | C+ (2.7) | C+ (2.6) |
| 2026-10-28 | B- (3.0) | D+ (1.5) | B- (2.9) | C+ (2.7) | C+ (2.7) | C+ (2.6) |
| 2026-10-21 | B- (3.0) | D+ (1.5) | B- (2.9) | C (2.4) | C+ (2.6) | C (2.5) |
| 2026-10-14 | B- (3.0) | D+ (1.5) | B- (2.9) | C (2.4) | C+ (2.6) | C+ (2.5) |